XLRN Key Statistics, Chart & Performance
The current stock price of XLRN is 178.75 null. In the past month the price increased by 2.76%. In the past year, price increased by 57.43%.
XLRN Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.3 | 405.82B | ||
| AMGN | AMGEN INC | 14.97 | 176.28B | ||
| GILD | GILEAD SCIENCES INC | 14.84 | 150.83B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.17 | 115.28B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.25 | 81.58B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 785.4 | 52.92B | ||
| INSM | INSMED INC | N/A | 37.49B | ||
| NTRA | NATERA INC | N/A | 31.28B | ||
| BIIB | BIOGEN INC | 10.54 | 25.88B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.54 | 21.07B | ||
| INCY | INCYTE CORP | 15.69 | 19.78B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.30B |
Related stock screener links
About XLRN
Company Profile
Acceleron Pharma, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of therapeutics to treat serious and rare diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 312 full-time employees. The company went IPO on 2013-09-18. The firm is focused on its research, development, and commercialization efforts in pulmonary and hematologic diseases. Its research is focused on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-beta) protein superfamily. The firm's product pipeline includes Sotatercept, ACE-1334 and REBLOZYL (luspatercept-aamt). Its lead pulmonary program, Sotatercept, is an activin receptor type IIA fusion protein that is used for the treatment of patients with pulmonary arterial hypertension (PAH). ACE-1334 is a wholly owned TGF-beta superfamily-based ligand trap designed to bind and inhibit TGF-beta 1 and 3 ligands but not TGF-beta 2. Its REBLOZYL (luspatercept-aamt), is an erythroid maturation agent designed to promote red blood cell (RBC).
Company Info
Acceleron Pharma
128 Sidney St
Cambridge MASSACHUSETTS 02139 US
CEO: Habib J. Dable
Employees: 312
Phone: 16176499200.0
Acceleron Pharma / XLRN FAQ
What does XLRN do?
Acceleron Pharma, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of therapeutics to treat serious and rare diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 312 full-time employees. The company went IPO on 2013-09-18. The firm is focused on its research, development, and commercialization efforts in pulmonary and hematologic diseases. Its research is focused on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-beta) protein superfamily. The firm's product pipeline includes Sotatercept, ACE-1334 and REBLOZYL (luspatercept-aamt). Its lead pulmonary program, Sotatercept, is an activin receptor type IIA fusion protein that is used for the treatment of patients with pulmonary arterial hypertension (PAH). ACE-1334 is a wholly owned TGF-beta superfamily-based ligand trap designed to bind and inhibit TGF-beta 1 and 3 ligands but not TGF-beta 2. Its REBLOZYL (luspatercept-aamt), is an erythroid maturation agent designed to promote red blood cell (RBC).
Can you provide the latest stock price for Acceleron Pharma?
The current stock price of XLRN is 178.75 null. The price decreased by -0.52% in the last trading session.
Does XLRN stock pay dividends?
XLRN does not pay a dividend.
How is the ChartMill rating for Acceleron Pharma?
XLRN has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the analyst forecast for XLRN stock?
17 analysts have analysed XLRN and the average price target is 182.68 null. This implies a price increase of 2.2% is expected in the next year compared to the current price of 178.75.
What is the market capitalization of XLRN stock?
Acceleron Pharma (XLRN) has a market capitalization of 10.89B null. This makes XLRN a Large Cap stock.
XLRN Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to XLRN. When comparing the yearly performance of all stocks, XLRN is one of the better performing stocks in the market, outperforming 93.05% of all stocks.
XLRN Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to XLRN. XLRN scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
XLRN Financial Highlights
Over the last trailing twelve months XLRN reported a non-GAAP Earnings per Share(EPS) of -4.21. The EPS decreased by -76.15% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -226% | ||
| ROA | -32.35% | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
XLRN Forecast & Estimates
17 analysts have analysed XLRN and the average price target is 182.68 null. This implies a price increase of 2.2% is expected in the next year compared to the current price of 178.75.
For the next year, analysts expect an EPS growth of -41.56% and a revenue growth 41.05% for XLRN